Michael S. Willis
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada.
Journal: Journal of comparative effectiveness research
Published: September 24, 2025
Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting.
Journal: Journal of medical economics
Published: June 12, 2025
A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care.
Journal: PharmacoEconomics
Published: February 18, 2025
Cost-effectiveness models of non-small cell lung cancer: A systematic literature review.
Journal: Journal of managed care & specialty pharmacy
Published: January 02, 2025
Budget impact models for lung cancer interventions: A systematic literature review.
Journal: Journal of managed care & specialty pharmacy
Published: August 30, 2024
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes.
Journal: Applied health economics and health policy
Published: August 20, 2024
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: January 09, 2024
Real-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics.
Journal: Blood pressure monitoring
Published: February 02, 2023
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.
Journal: Clinical lung cancer
Published: September 29, 2022
Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Journal: Applied health economics and health policy
Published: April 20, 2022
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Journal: Applied health economics and health policy
Published: February 27, 2022
Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium.
Journal: Acta clinica Belgica
Published: December 27, 2021
Last Updated: 09/26/2026